Navigation Links
Nektar Therapeutics Reports Third Quarter 2009 Financial Results
Date:11/4/2009

- --- ---- --- Net loss $(30,967) $(37,038) $(94,843) $(111,118) ======== ======== ======== ========= Basic and diluted net loss per share $(0.33) $(0.40) $(1.02) $(1.20) Shares used in computing basic and diluted net loss per share 92,789 92,425 92,621 92,413 NEKTAR THERAPEUTICS CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) (unaudited) ASSETS September 30, 2009 December 31, 2008 (1) ------------------ ----------------- Current assets: Cash and cash equivalents $32,777 $155,584 Short-term investments 242,901 223,410 Accounts receivable, net of allowance 6,330 11,161 Inventory 8,930 9,319 Other current assets 7,275 6,746 ----- ----- Total current assets $298,213 $406,220 Property and equipment, net 74,624 73,578 Goodwill 76,501 76,501 Other assets 3,313 4,237 ----- ----- Total assets $452,651 $560,536 ======== ======== LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $6,397 $13,832 Accrued compensation 9,711 11,570 Accrued clinical trial expens
'/>"/>
SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Nektar to Announce Financial Results for the Third Quarter of 2009 on Wednesday, November 4, 2009, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics to Host Conference Call to Discuss Todays Announcement of a New Partnership for NKTR-118 and NKTR-119
3. AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation
4. Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City
5. Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets
6. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
7. Nektar Therapeutics Reports First Quarter 2009 Financial Results
8. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston
9. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
10. Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets
11. Nektar Announces Retirement of Irwin Lerner from Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... At the request of the AMA, the ... for the public comment period (Docket No. FAA-2014-0396) for ... established by Congress as part of the FAA Modernization ... the new deadline for comments as September 23, 2014. ... published in the Federal Register on July 25, 2014, ...
(Date:7/24/2014)... New York, NY - July 24, 2014 -- Keryx ... results from the long-term, randomized, active control Phase 3 ... ferric iron-based phosphate binder, for the treatment of hyperphosphatemia ... The PERFECTED study (PhosphatE binding and iRon delivery with ... the Journal of the American Society of Nephrology ...
(Date:7/24/2014)... CA (PRWEB) July 24, 2014 ... the Global Supply Chain of the biotech industry. ... SCM Innovation Awards, brought to you by the ... global organization of supply chain management professionals for ... given to stakeholders of the Biotech industry – ...
(Date:7/24/2014)... PARK, Calif. , July 24, 2014 /PRNewswire/ ... company in the emerging field of regenerative medicine, ... webcast of a presentation to investors on Tuesday, ... p.m. PDT.  The presentation will include an overview ... To access the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics ...
Breaking Biology Technology:FAA Grants Comment Extension at the Request of AMA 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
... leading,supplier of virtual reality based training applications within the ... of the Board and,Goran Malmberg as President and CEO ... and brings with him a vast,array of experience in ... of several Swiss private and charitable foundations. Mr.,Ruscoe is ...
... Ltd. (ASX: PXL),CEO Dr Jenny Harry has been ... in Washington DC at the Partnering for Global ... Foundation and organised by Bio,Ventures in Global Health, ... http://pgh.bio.org/opencms/PGH/2008/program/program.jsp , The Forum follows a report ...
... researchers at the National Institute of Standards and ... in solution as they dart around in three ... plans to patent, will lead to a better ... and, ultimately, process control techniques to optimize the ...
Cached Biology Technology:Mentice AB Announces Leadership Changes Within Its Worldwide Operations 2The Bill & Melinda Gates Foundation, BIO, and Bio Ventures for Global Health Invite Proteome Systems' CEO to Speak on TB Diagnostics Solutions At Partnering for Global Health Forum, Washington D.C. 2The Bill & Melinda Gates Foundation, BIO, and Bio Ventures for Global Health Invite Proteome Systems' CEO to Speak on TB Diagnostics Solutions At Partnering for Global Health Forum, Washington D.C. 3All done with mirrors: NIST microscope tracks nanoparticles in 3-D 2
(Date:7/25/2014)... at the University of Houston, has written a ... development., "Introduction to Tissue Engineering: Applications and Challenges" ... field of artificial organ development. Metin Akay, founding ... served as a series editor on the book., ... books on the subject of growing artificial organs ...
(Date:7/25/2014)... research at the University of Adelaide has opened the way ... to powdery mildew. , In Australia, annual barley production is ... Powdery mildew is one of the most important diseases of ... have discovered the composition of special growths on the cell ... fungus into the leaf. , The research, by the ARC ...
(Date:7/25/2014)... (SB) is a complex congenital central nervous system ... of the neural tubes during the embryonic phase. ... and fecal incontinence and neurocognitive retardation. Such problems ... of life. Researchers at Ankara Physical Medicine and ... functional performance in children with SB, using the ...
Breaking Biology News(10 mins):University of Houston researcher publishes textbook on tissue engineering 2New hope for powdery mildew resistant barley 2
... FINDINGS: Short pieces of RNA, called microRNAs, control protein ... as messenger RNA or mRNA) to be disabled by ... Researchers have known that mammalian microRNAs control protein production ... wondered how much additional effects microRNAs impart by jamming ...
... OTO EXPO of the American Academy of Otolaryngology Head ... nose, and throat doctors in the world, will convene September ... 305 scientific research sessions, 594 posters, and several hundred instruction ... opportunity for journalists from around the world to cover breaking ...
... the cause of some of the most repugnant smells on ... forms actually has a sense of smell of its own. ... for the first time that bacteria have a molecular "nose" ... ammonia. Published today in Biotechnology Journal , their study ...
Cached Biology News:RNA snippets control protein production by disabling mRNAs 2RNA snippets control protein production by disabling mRNAs 3Bacteria breakthrough is heaven scent 2
... The ProteinChip Antibody Capture ... development and optimization steps ... antibody-antigen interactions. This kit ... differentiation of multiple antigens ...
...
... CLS number is a new product ... product number. If showing no availability ... Sigma-Aldrich number (R4276) or contact customer ... polystyrene (expanded surface, easy grip) ...
... Services offer a full range of peptide ... Services include: Peptide synthesis, crude product ... synthesis, purified product (70-95% pure) ... fluorescein, myristylation, phosphorylation, and rhodamine) ...
Biology Products: